Hydroxychloroquine and Azithromycin as a treatment of COVID-19: preliminary results of an open-label non-randomized clinical trial
Philippe GAUTRET, Jean Christophe LAGIER, Philippe PAROLA, Van Thuan HOANG, Line MEDDED, Morgan MAILHE, Barbara DOUDIER, Johan COURJON, Valerie GIORDANENGO, Vera ESTEVES VIEIRA, Herve TISSOT DUPONT, Stephane HONORE, Philippe COLSON, Eric CHABRIERE, Bernard LA SCOLA, Jean Marc ROLAIN, Philippe BROUQUI, Didier RAOULT Sr.

doi: https://doi.org/10.1101/2020.03.16.20037135

This article is a preprint and has not been certified by peer review



https://www.medrxiv.org/content/10.1....full.pdf+html


Such results are promising and open the possibility of an international strategy to decision-makers to fight this emerging viral infection in real-time even if other strategies and research including vaccine development could be also effective, but only in the future. We therefore recommend that COVID-19 patients be treated with hydroxychloroquine and azithromycin to cure their infection and to limit the transmission of the virus to other people in order to curb the spread of COVID-19 in the world. Further works are also warranted to determine if these compounds could be useful as chemoprophylaxis to prevent the transmission of the virus, especially for healthcare workers.